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Abstract Pyrraline is an advanced Maillard reaction product 
formed by the non-enzymatic reaction initiated by glucose with 
lysine residues on proteins. This reaction involves an intermedi- 
ate, 3-deoxyglucosone, concentration of which is shown to be 
elevated in plasma and lenses during diabetes. Bovine lens alpha 
crystallins incubated with 3-deoxyglucosone showed that pyrra- 
line formation was a major modification and its quantification by 
two different methods revealed time-dependent accumulation. 
Pyrraline was quantified in normal, senile cataractous and 
diabetic lenses. Although a wide variation was observed, the 
mean value in cataractous lenses (mean_+S.E.: 48.4+12.67 
pmol/mg protein) was higher than in age-matched normal lenses 
(30.9 + 10.26 pmol). Surprisingly, in diabetic lenses, the mean 
value was lower than normal lenses (28.4+ 15.3 pmol). These 
results suggest hat glucose-specific advanced Maillard products 
occur in the human lens and such modifications may play a role in 
lens aging and cataract formation. 
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1. Introduction 
Advanced Maillard reaction products derived from non-en- 
zymatic glycosylation of proteins by reducing sugars have 
been implicated in protein aging and pathogenesis of diabetic 
complications. The human lens was one of the first tissues to 
be studied for the role of Maillard reaction in protein aging, 
since proteins here hardly turn over and thus are expected to 
accumulate advanced Maillard products. The detection of the 
initial product of glycation (Amadori product), and its in- 
crease in aging and cataractous lenses uggested that glycation 
may in part be responsible for protein aggregation, crosslink- 
ing and pigmentation. Evidence for the presence of advanced 
Maillard products was mostly indirect, measured as protein- 
bound fluorescence. However, the protein-bound fluorescence 
can originate not only from the Maillard reaction, but also 
from the reaction of lipid peroxidation products. Thus, the 
specific effects of advanced Maillard products could not be 
appreciated. Recently, evidence for the advanced Maillard 
reaction in the human lens has been provided by the detection 
of specific products, LM-1, pentosidine and carboxymethyl 
lysine (CML) [1-3]. Their progressive accumulation i aging, 
and higher levels in cataractous lenses compared to age- 
matched normal lenses provided further evidence for a role 
for advanced Maillard reaction in lens protein aging and cat- 
aractogenesis. 
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Studies on the synthetic mechanisms for the advanced Mail- 
lard products described above have shown that they can be 
synthesized by a variety of sugars other than glucose, includ- 
ing ascorbate oxidation products [2,4,5]. In fact, previous tud- 
ies have implicated ascorbate oxidation products as the major 
precursors for LM-1 and pentosidine in the lens [1,2,5,6]. The 
only exception to this is pyrraline, an advanced Maillard re- 
action product also shown to be present in vivo (Fig. 3). 
Pyrraline is synthesized by glucose through an intermediate, 
3-deoxyglucosone. The presence of 3-deoxyglucosone i  plas- 
ma and its elevation in diabetes have been demonstrated in 
recent reports [7,8]. Its increase in diabetic lenses has been 
established in experimental nimals [9], and has been sug- 
gested to occur through polyol pathway intermediates [10]. 
It can also form from the Amadori product directly [11]. 
Although pyrraline formation in vivo is disputed in a recent 
report [12], several studies using immunochemical and chro- 
matographic methods have demonstrated itspresence in vivo 
[13 15]. Our recent study has shown that pyrraline can form 
pyrraline-pyrraline and pyrraline-cysteine crosslinks, which 
may explain in part protein crosslinking in aging and diabetes 
[16]. Since protein glycation by glucose is enhanced and the 
polyol pathway is activated in diabetic lenses, we hypothesized 
that these events may lead to increased formation of pyrraline. 
In this study, we report the synthesis of pyrraline in lens 
crystallins incubated with 3-DG and present quantitative 
data on pyrraline in normal, cataractous and diabetic lenses. 
2. Materials and methods 
Human lenses were obtained from the Cleveland Eye Bank and the 
National Disease Research Interchange (NDRI), Philadelphia, PA, 
Cataractous lenses were obtained from the Department of Ophthal- 
mology, University Hospitals of Cleveland, Cleveland, OH. Bovine 
lens c~-crystallins were a kind gift from Dr. Krishna Sharma, Univer- 
sity of Missouri, Columbia, MO. Pronase E (from Streptomyces gri- 
seus), peptidase (from porcine intestinal mucosa) and barium hydrox- 
ide octahydrate were from Sigma Chemical Co. All other reagents 
were of analytical grade. Pyrraline was purified from glucose-lysine 
incubation mixture as described before [13]. 3-Deoxyglucosone was 
synthesized bythe method of Madson and Feather [17]. 
2.1. Incubation of ot-crystallins with 3-deoxyglucosone 
c~-Crystallin at a concentration of 100 mg/ml was incubated with 
100 mM 3-DG in phosphate-buffered saline (PBS) at 37°C. Aliquots 
of 0.4 ml were withdrawn on day 0, 4, 8, 12 and 19 and dialyzed 
against 2× 2 1 PBS at 4°C for 48 h. The dialyzed fractions were stored 
at -80°C until use. Proteins incubated without he sugar served as 
control. 
2.2. Enzymatic digestion 
5 mg proteins (lens c~-crystallins cubated with or without 3-DG) 
were taken in 400 /.tl phosphate-buffered saline (PBS). To this 1% 
peptidase (w/w) was added and incubated at 37°C for 16 h. The 
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Fig. 1. SDS-polyacrylamide g l electrophoresis of bovine ~t-crystal- 
lins incubated with 3-deoxyglucosone. Lane 1, protein standards; 
lanes 2, 3, 4 and 5 are crystallins incubated without 3-DG for 4, 8, 
12 and 19 days, respectively, and lanes 6, 7, 8, 9, 10 are crystallins 
incubated with 3-DG for 0, 4, 8, 12 and 19 days, respectively. 
digestion was continued with the addition of pronase E (1%, w/w) for 
16 h. After digestion, the samples were clarified by centrifugation at
3500xg for 15 min and filtered through 0.45 gin centrifugal filters 
(Rainin Instruments Co. Inc., Woburn, MA). 
2.3. Barium hydroxide hydrolysis 
5 mg lens proteins (incubated with or without 3-DG) were taken in 
a screw capped tube and 1.5 ml water and 800 mg barium hydroxide 
octahydrate were added. Hydrolysis was carried out at 120°C for 24 h. 
The pH of the hydrolyzate was adjusted between 7 and 8 with 4 N 
H2SO4. The solution was then centrifuged at 14000×g for 30 min. 
The supernatant was taken out and dried in a Speed Vac Concentra- 
tor (Savant Instruments, Farmingdale, NY). In the case of human 
lenses, tissue corresponding to 100 mg wet weight was minced into 
small pieces, and digested with barium hydroxide (2.5 g) in 4.8 ml 
water. Other procedures were as described above. In the protein di- 
gests obtained by the above methods, amino acid estimation was done 
by the method of Moore and Stein using L-leucine as standard [18]. 
2.4. HPLC assay of pyrraline 
Pyrraline estimation was accomplished by HPLC using a Cas re- 
versed phase column (10 gm, Vydac, The Separations Group, Hesper- 
ia, CA). The mobile phase consisted of water (A) and 50% acetonitrile 
in water (B) and with 0.1% trifluoroacetic acid (TFA). The gradient 
program was as follows 0-10 min: 0-15% B; 10-40 min: 15-25% B; 
42-49 min: 100% B and 50-57 min: 0% B at a flow rate of 1.2 ml per 
rain. The column eluate was monitored for absorbance at 298 nm. 
Pyrraline standard eluted at 16.8 min. In the case of enzyme digested 
samples, the mobile phase B was 60% acetonitrile in water with 0.01 
M heptafluorobutyric a id (HFBA). The column was eluted with a 
linear gradient of B from 0 to 35 min at a flow rate of 1.0 ml per min. 
Pyrraline standard eluted at about 15.0 rain under these conditions. 
In the case of human lenses, the mobile phase was water/acetonitrile 
with 0.1% TFA a described above. The gradient program was as 
follows: ~10 min: 0-29% B, 2040 min: 29-57% B; 41-47 rain: 
100% B and 48 58 min: 0% B. Pyrraline standard eluted at 19 min. 
Since pyrraline was not well resolved pyrraline containing eluate 
(from 17 to 22 min) was collected, pH was adjusted to 7.0 by 1 N 
NaOH and dried. The dried material was reconstituted in 200 gl water 
(+0.01 M HFBA) and subjected again to HPLC on a reversed phase 
column using the following program (solvent A: water+0.1 M 
HFBA, solvent B: 60% acetonitrile in water+0.01 M HFBA; 0-15 
min: 0-20% B; 15-20 min: 20-25% B; 2ff40 min: 25-42% B; 41 
48 min: 100% B; 4%56 min: 100% A. Pyrraline eluted at 24.5 min. 
Pyrraline was quantified in the lenses by comparing with the peak 
area of the standard and expressed as pmoles/mg protein by consider- 
ing the molecular weight of lens cystallins as 20 000 kDa. 
2.5. Purification of pyrraline from brunescent lenses 
Human brunescent lenses (pool of five) were extracted into water 
soluble and insoluble fractions as described previously [1]. The water 
insoluble fraction (50 mg) was digested with barium hydroxide and 
subjected to HPLC using a ClS reversed phase semi-preparative col- 
umn (10 /am, Vydac). The HPLC eluate corresponding to the reten- 
tion time of pyrraline standard was collected and reinjected for further 
purification as described above for the human lenses, except hat the 
flow rate was set at 2.0 ml per min. The absorption spectrum of 
pyrraline was recorded by an on-line UV/vis absorbance detector 
(model 975, Jasco Corp., Japan). 
SDS-PAGE was performed on a 12.5% gel in the presence of mer- 
captoethanol. Briefly, 25 gg of proteins was applied to each lane with 
4% stacking gel. The gel was run at 40 mA and stained with Coo- 
massie brilliant blue. 
3. Results 
Bovine lens tx-crystallins incubated with 3-deoxyglucosone 
progressively turned yellow and underwent crosslinking. SDS- 
PAGE (Fig. I) showed the formation of dimers and some 
polymers after only 4 days of incubation. After 8 days, there 
was a significant reduction in monomers and formation of 
protein polymers. Most of the protein turned polymeric after 
12 days of incubation. The absorpt ion spectra showed that 
pyrraline may be a major  modification in these incubations, 
since the region where pyrraline has maximum absorbance 
(between 285 and 320 nm) increased as a function of time 
(Fig. 2). 
Pyrraline was quantified in the incubated samples by two 
methods. The bar ium hydroxide hydrolysis followed by 
HPLC showed a distinct peak corresponding to the retention 
time of purified pyrral ine (not shown). This peak had the 
absorpt ion spectra (scanned by the on-line detector) identical 
to that of purified pyrral ine (not shown). Pyrraline level in- 
creased as a function of time and reached 419 pmol/mg pro- 
tein after 19 days of incubation (Fig. 3). We also tested 
whether pyrraline could be released from protein by enzyme 
digestion and whether this method could be used for its quan- 
tification in proteins. Sequential addit ion of peptidase and 
pronase was efficient in releasing pyrraline. HPLC of the di- 
gested material showed a well separated peak at 15.3 min, 
which was identical to the retention of purified pyrraline 
(Fig. 4). The samples which were spiked with purified pyrra- 
0.5 
m 
o t-- 
o 
.o ,< 
19 
0.0 , , , , 
210 248 286 324 362 400 
Wavelength (nm) 
Fig. 2. Absorption spectra of bovine ct-crystallins incubated with 
3-deoxyglucosone. 
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Fig. 3. Formation of pyrraline in bovine c~-crystallins incubated 
with 3-deoxyglucosone. Pyrraline was estimated by HPLC either 
after enzyme digestion (O) or after barium hydroxide hydrolysis (©). 
Inset shows the structure of pyrraline. 
line showed one single peak with a corresponding increase in 
the peak area. Pyrraline level measured by this method was 
about 3 times higher than the barium hydroxide method. After 
19 days of incubation 1354 pmol/mg protein had formed (Fig. 
3). The difference between the two methods could be due to 
partial destruction of pyrraline by alkaline hydrolysis or due 
to overestimation of pyrraline due to contamination of the 
peak in HPLC in the method with enzyme digestion. How- 
ever, for quantification i lenses barium hydroxide hydrolysis 
was employed for the reason described below. Proteins incu- 
bated without 3-DG did not show pyrraline in these methods. 
To establish the presence of pyrraline in the human lens, an 
attempt was made to purify from protein of highly pigmented 
brunescent lenses. Our attempts to employ enzyme digestion 
were unsuccessful possibly due to insufficient digestion of the 
highly crosslinked proteins. The barium hydroxide hydrolysis 
method, on the other hand, showed the presence of pyrraline. 
Since the pyrraline peak was not well resolved uring the first 
HPLC, we collected the effluent containing pyrraline, dried 
and reinjeeted onto HPLC under a different condition. A 
well resolved peak was observed at 27.4 rain, which was simi- 
lar to the retention time of purified pyrraline (Fig. 5). The 
absorption spectrum of this peak was fully compatible with 
that of purified pyrraline. This preparation of pyrraline when 
mixed with pyrraline prepared from lysine-glucose incubation 
and subjected to HPLC eluted as a single peak. These obser- 
vations confirm the presence of pyrraline in the human lens. 
However, mass spectral data is required as additional confir- 
matory evidence. The amount of purified material was not 
enough to perform this analysis. 
Our attempt o quantify pyrraline in the water soluble and 
insoluble fractions of the lens separately was not successful by 
either enzymatic or barium hydroxide hydrolysis method. It 
was then decided to use lenses without protein extraction 
(about 100 mg wet weight). Barium hydroxide hydrolysis, fol- 
lowed by two-step HPLC was employed. Pyrraline standard 
was processed similarly for comparison. Seven normal, 10 
cataractous lenses (senile, nuclear) and 8 diabetic lenses (not 
cataractous) were used. A wide variation of pyrraline was 
observed in these lenses (Fig. 6). The mean level however 
was higher in cataractous lenses (mean+S.E,, 48.4_+ 12.67 
pmol/mg protein) when compared with normal lenses 
(30.93 + 10.26 pmol). Surprisingly in diabetic lenses, levels in 
general were lower than normal lenses (28.4+ 15.38 pmol). 
Interestingly, one normal, 2 cataractous and one lens in dia- 
betic group showed extremely high levels. The pyrraline con- 
tent in normal, senile cataractous and diabetic lenses ac- 
counted for 666, 968 and 570 gmol/mol crystallins, 
respectively. This corresponded to 0.095, 0.13 and 0.081% 
lysine modification in ~-crystallins, respectively. Due to large 
differences in the range of pyrraline within groups, means 
were compared by a nonparametric statistic (Mann-Whitney 
U-test). No significant difference (P > 0.05) in the scores be- 
tween any two groups was observed. 
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Fig. 4. Representative chromatograms showing pyrraline peak in 
c~-crystallins incubated with 3-DG. A, pyrraline standard and B, 
crystallins incubated with 3-DG for 12 days. 
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Fig. 5. Purification of pyrraline from human brunescent lenses. The 
pyrraline peak (in panel B) was obtained uring the final step of 
purification. The chromatogram for pyrraline is shown in panel A. 
The inset shows the absorption spectrum of pyrraline purified from 
brunescent lenses. 
4. Discussion 
The purpose of this study was to investigate he presence of 
pyrraline in the human lens and its relation to cataract for- 
mation. In vitro experiments with c~-crystallins showed that 
pyrraline can rapidly form when incubated with 3-deoxyglu- 
cosone. The absorption spectra of crystallins incubated with 
3-DG clearly showed that pyrraline was a major modification. 
However, formation of pyrraline can not account for the ex- 
tensive crosslinking of proteins observed in SDS-PAGE, since 
it by itself is a non-crosslinking product. It is possible how- 
ever, that pyrraline formed on proteins may induce covalent 
crosslinking through oxidation by forming dipyrraline (pyrra- 
line-pyrraline ther crosslinking), and thioether crosslinking 
with cysteine residues, as reported recently [16]. Under the 
incubation conditions used, other advanced Maillard reaction 
products are also likely to form. This is substantiated by the 
data on protein-fluorescence (excitation/emission 370/440 nm), 
which increased progressively in crystallins incubated with 3- 
DG (not shown). The formation of pyrrolopyridinium cross- 
link by the reaction of 3-DG with butylamine has been docu- 
mented [19]. 3-DG is also a potent modifier of arginine resi- 
dues on proteins. The structure of arginine modification has 
been recently reported [20]. 
The presence of pyrraline in normal non-cataractous lenses 
suggests that 3-deoxyglucosone is formed in these lenses. This 
is in agreement with the observation of Lal et al. [9] that 
poyol pathway metabolites, which are precursors of 3-DG 
are present in normal lenses. 3-Deoxyglucosone can also 
form from the Amadori product of the reaction between glu- 
cose with proteins [11]. The slightly acidic pH of the lens may 
promote the formation of 3-DG from Amadori products. The 
elevated levels in cataractous lenses reflects higher levels of 
Amadori products in these lenses. The wide range of distribu- 
tion of pyrraline suggest that it may be oxidized or modified 
to different degrees in individual lenses due to differences in 
oxidative stress or cellular constituents reactive with pyrraline, 
e.g. glutathione [16]. 
Surprisingly, in the majority of diabetic lenses, the levels 
were lower than normal enses. Considering the fact that poly- 
ol pathway and glycation are enhanced in diabetic lenses, it 
was expected that pyrraline levels would be higher in these 
lenses. One likely explanation for the lower levels is, increased 
oxidation of pyrraline in diabetes because of enhanced oxida- 
tive stress. Several studies have shown an enhancement in 
oxidative stress in diabetic lenses [21]. This may result in pyr- 
raline ether crosslinking [16], leading to decreased levels of 
unmodified pyrraline. Alternatively, metabolism of 3-DG by 
activated aldose reductase [22] in diabetic lens may limit the 
formation of pyrraline. It should be pointed out here that the 
diabetic lenses used were not cataractous, but were only 
highly pigmented. It is interesting to note that in some lenses 
pyrraline levels were extremely high, reasons for this are un- 
known. It is noteworthy here that the presence of nephropa- 
thy in diabetic patients greatly enhances serum 3-DG level [8]. 
Whether this will have any effect on lens pyrraline remains to 
be investigated. 
In summary, the demonstration f pyrraline in the human 
lens offers a probe to assess glucose-specific modification in 
lens aging and cataract formation. Although pyrraline may 
not itself contribute significantly to protein aggregation, its 
formation may compromise the ability of ~-crystallins to 
function as a molecular chaperone [23] in analogy to the ob- 
servation of Cherian and Abraham [24]. 
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